Corbion Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 4/6
CorbionDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -11.1% zurückgegangen, während in der Branche Chemicals die Gewinne mit einer durchschnittlichen jährlichen Rate von 12.2% zurückgehen. Die Umsatzerlöse sind gewachsen mit einer durchschnittlichen Rate von 4.5% pro Jahr. Corbion Die Eigenkapitalrendite des Unternehmens beträgt 10.1%, und die Nettomargen liegen bei 5.9%.
Wichtige Informationen
-11.08%
Wachstumsrate der Gewinne
-10.79%
EPS-Wachstumsrate
| Chemicals Wachstum der Industrie | 1.60% |
| Wachstumsrate der Einnahmen | 4.46% |
| Eigenkapitalrendite | 10.07% |
| Netto-Marge | 5.90% |
| Nächste Ertragsaktualisierung | 31 Jul 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrativ-Update • May 09
CRBN: Special Dividend And Higher Future P E Could Support Re Rating
Analysts have reduced their fair value estimate for Corbion from €30.00 to €28.00, citing updated assumptions for revenue growth, profit margins and future P/E following recent research, including the Barclays downgrade. Analyst Commentary Recent research has led to a lower fair value estimate for Corbion, but bullish analysts still highlight several supports for the stock, focusing on how current assumptions around revenue, margins and P/E could play out over time.
Narrativ-Update • Apr 22
CRBN: Special Dividend And Execution On Margins Will Support Upside Potential
The updated analyst price target for Corbion has shifted slightly to about €24.03 from €24.17, as analysts adjust their assumptions around discount rate, revenue growth, profit margin and future P/E in light of recent research, including the Barclays downgrade. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target around €24.03 as still leaving some room for upside if Corbion executes well on its revenue and margin assumptions embedded in the models.
Narrativ-Update • Apr 08
CRBN: Raised Fair Value And Barclays Downgrade Will Shape Risk Balance
Analysts now set Corbion's fair value at €19.60, up from €18.60. This reflects updated assumptions on growth, margins and P/E multiples, even as some recent research, including a downgrade at Barclays, highlights ongoing risks.Narrativ-Update • Mar 24
CRBN: Higher Margins And Special Dividend Will Support Future Re Rating
Analysts have maintained their price target for Corbion at €30.00, citing updated assumptions around the discount rate, revenue growth, profit margin and future P/E as the main factors supporting the unchanged view. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share, planned for distribution in 2025.Narrativ-Update • Mar 10
CRBN: Special Dividend And Stronger Margins Will Support A More Optimistic Outlook
Analysts have trimmed their price target on Corbion from €24.60 to about €24.17, reflecting updated views on its projected revenue growth, profit margins, and future P/E assumptions. What's in the News Corbion N.V. proposed a special dividend of €0.36 per share for 2025, which may influence your expected cash returns from holding the stock (Key Developments).Narrativ-Update • Feb 24
CRBN: Higher Future P/E Assumptions Will Support A More Optimistic Outlook
Analysts have raised their price target on Corbion from about €22.73 to €24.60, citing updated assumptions on discount rates, revenue growth, profit margins, and future P/E levels. Valuation Changes Fair Value: Updated estimate increased from about €22.73 to €24.60 per share.Narrativ-Update • Feb 09
CRBN: Buyback And Higher Discount Rate Will Pressure Overvalued Shares
Analysts have kept their price target on Corbion steady at €18.60, citing only small adjustments to assumptions around the discount rate, revenue trends, profit margins and future P/E as the basis for this unchanged view. What's in the News Corbion completed a share buyback program, repurchasing 577,615 shares for €10 million, equal to 0.99% of the company.Narrativ-Update • Jan 26
CRBN: Higher Future P/E And Execution Risks Will Shape EUR 18 Outlook
Narrative Update on Corbion Analysts have raised their fair value estimate for Corbion to €18.60 from €18.00. This reflects updated views on discount rates, long term revenue trends, profit margins, and a higher future P/E assumption, alongside recent Street research where a key price target moved to €18 from €16.50.Analyseartikel • Jan 14
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it saw a double-digit share price rise of over 10...Narrativ-Update • Jan 11
CRBN: Future P/E Reset And Margin Assumptions Will Shape EUR 18 Outlook
Analysts have raised their price target for Corbion to €18 from €16.50, citing updated assumptions on revenue trends, margins and future P/E as the main factors behind the change. Analyst Commentary The revised €18 price target still comes with a Hold stance, which signals a measured view on Corbion.Narrativ-Update • Dec 26
CRBN: Higher EUR 18 Outlook Will Test Margin Delivery Amid Muted Demand
Analysts have raised their fair value estimate for Corbion to EUR 18 from EUR 14, reflecting increased confidence in the company’s profit margin outlook and a willingness to apply a higher future earnings multiple despite more muted revenue growth expectations. Analyst Commentary Bearish analysts acknowledge the higher fair value estimate but continue to highlight a cautious stance on Corbion’s near term prospects, emphasizing that the improved target largely reflects valuation mechanics rather than a fundamental re-rating of the growth outlook.Narrativ-Update • Dec 12
CRBN: Margin Improvements And Buybacks Will Support A Future Re-Rating
Analysts have lowered their fair value price target on Corbion to EUR 30.00 from EUR 31.90, citing tempered expectations for long term revenue growth and profit margins, even as some recent Street research has modestly raised nearer term share price targets. Analyst Commentary Bullish analysts highlight that the recent upward revision in near term price targets, even from a relatively low base, reflects growing confidence that Corbion can stabilize its earnings profile and execute on margin improvement initiatives.Analyseartikel • Nov 14
Corbion N.V. (AMS:CRBN) Shares Could Be 35% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €28.50 Current share price of...Analyseartikel • Jun 23
Corbion N.V.'s (AMS:CRBN) Intrinsic Value Is Potentially 65% Above Its Share Price
Key Insights The projected fair value for Corbion is €30.72 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • May 07
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely
Key Insights Corbion's Annual General Meeting to take place on 14th of May Salary of €725.0k is part of CEO Olivier...Analyseartikel • Apr 10
At €17.39, Is Corbion N.V. (AMS:CRBN) Worth Looking At Closely?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw significant share price movement during recent...Analyseartikel • Mar 26
Corbion's (AMS:CRBN) Earnings May Just Be The Starting Point
Corbion N.V.'s ( AMS:CRBN ) earnings announcement last week was disappointing for investors, despite the decent profit...
Neues Narrativ • Mar 02
Expanding Into Natural Antioxidants And Efficiency Improvements Will Drive Future Success
Strategic initiatives and operational optimizations are expected to significantly enhance EBITDA margins and net margins.Analyseartikel • Feb 28
Here's What To Make Of Corbion's (AMS:CRBN) Decelerating Rates Of Return
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Corbion N.V. (AMS:CRBN)
It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 15.8x right now seems...Analyseartikel • Nov 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it received a lot of attention from a substantial price...Analyseartikel • Oct 31
An Intrinsic Calculation For Corbion N.V. (AMS:CRBN) Suggests It's 26% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €31.60 Corbion's €23.28 share...Analyseartikel • Sep 26
Corbion (AMS:CRBN) Takes On Some Risk With Its Use Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analyseartikel • Jul 18
The Price Is Right For Corbion N.V. (AMS:CRBN)
It's not a stretch to say that Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 16.1x right now seems...Analyseartikel • Jun 20
Corbion N.V. (AMS:CRBN) Shares Could Be 25% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €25.18 Corbion is estimated to...Analyseartikel • May 08
Here's Why Shareholders Should Examine Corbion N.V.'s (AMS:CRBN) CEO Compensation Package More Closely
Key Insights Corbion will host its Annual General Meeting on 15th of May Salary of €713.0k is part of CEO Olivier...Analyseartikel • Apr 17
Does Corbion (AMS:CRBN) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jan 20
Investor Optimism Abounds Corbion N.V. (AMS:CRBN) But Growth Is Lacking
There wouldn't be many who think Corbion N.V.'s ( AMS:CRBN ) price-to-earnings (or "P/E") ratio of 14.3x is worth a...Analyseartikel • Dec 18
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...Analyseartikel • Nov 04
Estimating The Fair Value Of Corbion N.V. (AMS:CRBN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Corbion fair value estimate is €15.91 Corbion's €17.30 share...Analyseartikel • Sep 13
Corbion (AMS:CRBN) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Aug 04
Returns On Capital Signal Tricky Times Ahead For Corbion (AMS:CRBN)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...Analyseartikel • Jul 14
When Should You Buy Corbion N.V. (AMS:CRBN)?
While Corbion N.V. ( AMS:CRBN ) might not be the most widely known stock at the moment, it received a lot of attention...Analyseartikel • Jun 04
Corbion N.V. (AMS:CRBN) Shares Could Be 22% Above Their Intrinsic Value Estimate
Key Insights The projected fair value for Corbion is €21.22 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Apr 21
Here's Why Corbion (AMS:CRBN) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Mar 10
Corbion (AMS:CRBN) Is Paying Out A Dividend Of €0.56
Corbion N.V. ( AMS:CRBN ) has announced that it will pay a dividend of €0.56 per share on the 30th of May. The dividend...Analyseartikel • Feb 22
Is Now An Opportune Moment To Examine Corbion N.V. (AMS:CRBN)?
Corbion N.V. ( AMS:CRBN ), is not the largest company out there, but it received a lot of attention from a substantial...Analyseartikel • Jan 26
Corbion's (AMS:CRBN) Returns On Capital Not Reflecting Well On The Business
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analyseartikel • Dec 20
Is Corbion (AMS:CRBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Nov 24
Calculating The Intrinsic Value Of Corbion N.V. (AMS:CRBN)
Today we will run through one way of estimating the intrinsic value of Corbion N.V. ( AMS:CRBN ) by taking the expected...Analyseartikel • Nov 09
Should You Think About Buying Corbion N.V. (AMS:CRBN) Now?
Corbion N.V. ( AMS:CRBN ), might not be a large cap stock, but it saw a decent share price growth in the teens level on...Analyseartikel • Oct 08
Corbion (AMS:CRBN) Might Be Having Difficulty Using Its Capital Effectively
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie Corbion Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 25 | 1,267 | 75 | 174 | 43 |
| 30 Sep 25 | 1,282 | 70 | 178 | 44 |
| 30 Jun 25 | 1,297 | 66 | 182 | 45 |
| 31 Mar 25 | 1,292 | 56 | 182 | 45 |
| 31 Dec 24 | 1,288 | 46 | 183 | 46 |
| 30 Sep 24 | 1,274 | 48 | 180 | 46 |
| 30 Jun 24 | 1,260 | 50 | 177 | 45 |
| 31 Mar 24 | 1,262 | 47 | 176 | 45 |
| 31 Dec 23 | 1,264 | 43 | 176 | 46 |
| 30 Sep 23 | 1,338 | 48 | 178 | 47 |
| 30 Jun 23 | 1,412 | 54 | 180 | 48 |
| 31 Mar 23 | 1,435 | 72 | 176 | 48 |
| 31 Dec 22 | 1,458 | 90 | 171 | 47 |
| 30 Sep 22 | 1,350 | 76 | 167 | 46 |
| 30 Jun 22 | 1,243 | 63 | 162 | 46 |
| 31 Mar 22 | 1,157 | 70 | 158 | 44 |
| 31 Dec 21 | 1,071 | 78 | 155 | 43 |
| 30 Sep 21 | 1,040 | 97 | 149 | 41 |
| 30 Jun 21 | 1,010 | 116 | 144 | 40 |
| 31 Mar 21 | 998 | 95 | 142 | 38 |
| 31 Dec 20 | 987 | 73 | 140 | 37 |
| 30 Sep 20 | 992 | 49 | 143 | 35 |
| 30 Jun 20 | 997 | 24 | 147 | 32 |
| 31 Mar 20 | 987 | 25 | 147 | 33 |
| 31 Dec 19 | 976 | 26 | 146 | 35 |
| 30 Sep 19 | 953 | 37 | 141 | 38 |
| 30 Jun 19 | 930 | 48 | 135 | 42 |
| 31 Mar 19 | 914 | 51 | 132 | 41 |
| 31 Dec 18 | 897 | 54 | 129 | 39 |
| 30 Sep 18 | 883 | 61 | 128 | 37 |
| 30 Jun 18 | 869 | 69 | 126 | 35 |
| 31 Mar 18 | 880 | 77 | 126 | 34 |
| 31 Dec 17 | 892 | 85 | 126 | 33 |
| 30 Sep 17 | 905 | 87 | 128 | 32 |
| 30 Jun 17 | 918 | 89 | 130 | 32 |
| 31 Mar 17 | 914 | 95 | 128 | 31 |
| 31 Dec 16 | 911 | 102 | 126 | 31 |
| 30 Sep 16 | 917 | 103 | 124 | 33 |
| 30 Jun 16 | 922 | 104 | 122 | 34 |
| 31 Mar 16 | 920 | 91 | 122 | 33 |
| 31 Dec 15 | 918 | 78 | 121 | 33 |
| 30 Sep 15 | 885 | 45 | 119 | 32 |
| 30 Jun 15 | 851 | 13 | 118 | 31 |
Qualität der Erträge: CRBN hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: CRBNDie aktuellen Gewinnspannen (5.9%) sind höher als im letzten Jahr (3.6%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: CRBNDie Erträge des Unternehmens sind in den letzten 5 Jahren um 11.1% pro Jahr zurückgegangen.
Beschleunigtes Wachstum: CRBNDas Gewinnwachstum des Unternehmens im letzten Jahr (63%) übertrifft seinen 5-Jahres-Durchschnitt (-11.1% pro Jahr).
Erträge im Vergleich zur Industrie: CRBN Das Gewinnwachstum im vergangenen Jahr (63%) übertraf das der Branche Chemicals 32.3% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: CRBNDie Eigenkapitalrendite des Unternehmens (10.1%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/21 05:45 |
| Aktienkurs zum Tagesende | 2026/05/21 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Corbion N.V. wird von 13 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Setu Sharda | Barclays |
| Sebastian Bray | Berenberg |
| Fintan Ryan | Berenberg |